Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Study at GHU Paris Psychiatrie & Neurosciences in France

About this update from Red Light Holland Corp

Toronto, Ontario--(Newsfile Corp. - June 8, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company") is an Ontario based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived psilocybin development and Filament's patented botanical drug candidate, PEX010. The Company is pleased to announce that Filament has signed an agreement with GHU Paris Psychiatrie & Neurosciences ("GHU Paris"), a leading French university hospital group for psychiatry and neuroscience, to supply PEX010 in support of an academic clinical study titled "KETAPSYCHECOG: Effects of ketamine and psilocybin on behavioral and neural measures: a randomized, double blinded, cross-over study in healthy volunteers." The study is a randomized, double blinded, cross-over trial in healthy volunteers designed to compare the behavioral and neural effects of psilocybin and ketamine. PEX010 will be supplied for the psilocybin component of the study. Mechanistic research of this kind, conducted in healthy volunteers, complements the patient-population trials within the network by helping to characterize how naturally derived psilocybin acts on the brain. The agreement adds France to Filament's expanding international clinical research footprint and reflects Red Light's continued commitment to supporting independent research with GMP-compliant, standardized, naturally derived psilocybin. As academic and clinical interest in psilocybin continues to grow across new jurisdictions, the Company believes that a quality-controlled and regulatory-conscious supply framework will be an increasingly important factor in how this research is conducted and ultimately translated into care. PEX010 is Filament Health's patented botanical psilocybin drug candidate and is currently supplied to more than 80 studies worldwide, making it one of the most widely studied botanical psilocybin drug candidates in regulated clinical research. About Red Light Holland Red Light is an Ontario based organization advancing a focused strategy w...

View stock analysis, news, and events for Red Light Holland Corp